Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
Description
Brief Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39
enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP)
and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and
promote anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and
anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard
chemotherapies.
Phase
N/AInclusion and Exclusion Criteria
- Age 18 years or older, is willing and able to provide informed consent
- Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
- Life expectancy > 12 weeks
- ECOG performance status of 0-1 Abbreviated
- History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
- Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
- Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
- History of severe autoimmune disease
- Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI